146 related articles for article (PubMed ID: 6476782)
1. Biochemistry and clinical relevance of lipoprotein X.
Narayanan S
Ann Clin Lab Sci; 1984; 14(5):371-4. PubMed ID: 6476782
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-X.
Narayanan S
CRC Crit Rev Clin Lab Sci; 1979 Aug; 11(1):31-51. PubMed ID: 389551
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
4. Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.
O K; Frohlich J
J Lipid Res; 1995 Nov; 36(11):2344-54. PubMed ID: 8656072
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the structure and metabolism of lipoprotein-X (LP-X), the abnormal plasmalipoprotein in cholestasis (author's transl)].
Seidel D
Klin Wochenschr; 1977 Jul; 55(13):611-23. PubMed ID: 197298
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro relationship between lipoprotein-X and bile salts in cholestasis.
Frisón JC; Ras MR; Rubiés-Prat J; Salvá JA; Masdeu S; Bacardí R
Digestion; 1979; 19(6):411-4. PubMed ID: 535670
[TBL] [Abstract][Full Text] [Related]
7. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.
Amar MJA; Freeman LA; Nishida T; Sampson ML; Pryor M; Vaisman BL; Neufeld EB; Karathanasis SK; Remaley AT
Pharmacol Res Perspect; 2020 Feb; 8(1):e00554. PubMed ID: 31893124
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
9. Formation of lipoprotein-X. Its relationship to bile compounds.
Manzato E; Fellin R; Baggio G; Walch S; Neubeck W; Seidel D
J Clin Invest; 1976 May; 57(5):1248-60. PubMed ID: 816809
[TBL] [Abstract][Full Text] [Related]
10. Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.
Nishiwaki M; Ikewaki K; Bader G; Nazih H; Hannuksela M; Remaley AT; Shamburek RD; Brewer HB
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1370-5. PubMed ID: 16543491
[TBL] [Abstract][Full Text] [Related]
11. [Abnormal lipoprotein (LP-X) in the first months of life with particular reference to obstructive jaundice (author's transl)].
Lachmann D
Wien Klin Wochenschr Suppl; 1977; 69():3-28. PubMed ID: 266315
[TBL] [Abstract][Full Text] [Related]
12. Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.
Freeman LA; Shamburek RD; Sampson ML; Neufeld EB; Sato M; Karathanasis SK; Remaley AT
J Lipid Res; 2019 May; 60(5):1050-1057. PubMed ID: 30808683
[TBL] [Abstract][Full Text] [Related]
13. Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.
Heimerl S; Boettcher A; Kaul H; Liebisch G
Biochim Biophys Acta; 2016 Aug; 1861(8 Pt A):681-7. PubMed ID: 27112638
[TBL] [Abstract][Full Text] [Related]
14. [The significance of LP-X cholesterol in the differential diagnosis of cholestasis (author's transl)].
Wieland H; Meissner-Heins H; Heins C; Seidel D
Klin Wochenschr; 1982 Apr; 60(7):343-8. PubMed ID: 7078029
[TBL] [Abstract][Full Text] [Related]
15. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer.
Sivakumar T; Chaidarun S; Lee HK; Cervinski M; Comi R
J Clin Lipidol; 2011; 5(4):324-8. PubMed ID: 21784379
[TBL] [Abstract][Full Text] [Related]
16. A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects.
Seidel D; Alaupovic P; Furman RH
J Clin Invest; 1969 Jul; 48(7):1211-23. PubMed ID: 4978447
[TBL] [Abstract][Full Text] [Related]
17. Quantification of lipoprotein X and its relationship to plasma lipid profile during different types of parenteral nutrition.
Rigaud D; Serog P; Legrand A; Cerf M; Apfelbaum M; Bonfils S
JPEN J Parenter Enteral Nutr; 1984; 8(5):529-34. PubMed ID: 6436526
[TBL] [Abstract][Full Text] [Related]
18. A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins.
Seidel D; Alaupovic P; Furman RH; McConathy WJ
J Clin Invest; 1970 Dec; 49(12):2396-407. PubMed ID: 5480863
[TBL] [Abstract][Full Text] [Related]
19. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Walli AK; Seidel D
J Clin Invest; 1984 Sep; 74(3):867-79. PubMed ID: 6470142
[TBL] [Abstract][Full Text] [Related]
20. Differences in reaction specificity toward lipoprotein X and abnormal LDL among 6 homogeneous assays for LDL-cholesterol.
Matsushima K; Sugiuchi H; Anraku K; Nishimura H; Manabe M; Ikeda K; Ando Y; Kondo Y; Ishitsuka Y; Irikura M; Irie T
Clin Chim Acta; 2015 Jan; 439():29-37. PubMed ID: 25286006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
